Clearbridge Health Ltd. (1H3) AI Stock Analysis

• Market Cap: S$8.59M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SG
• Employees: 128
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 4,295,821,000
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: <0.01
• Price to Book (P/B): 0.30
• Price to Sales (P/S): 0.28
• P/FCF Ratio: -1.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: <S$0.01 ▼(-10.00% Downside)
• Action: Reiterated Date: 10/29/25
• Date: Action: Reiterated 10/29/25

Clearbridge Health Ltd. is currently facing significant financial difficulties, with ongoing losses and negative cash flows being the most critical issues. The lack of technical and valuation data further complicates the assessment, resulting in a low overall stock score. Immediate attention to financial performance is necessary to improve the company's outlook.

Positive Factors

Strategic Placement

The strategic placement enhances liquidity and provides capital for growth opportunities, supporting long-term competitiveness and shareholder value.

Convertible Bond Maturity Extension

Extending bond maturity provides financial flexibility, allowing the company to manage current challenges and focus on long-term strategic goals.

Stable Gross Profit Margin

A stable gross profit margin indicates consistent cost management and pricing strategy, supporting long-term financial health despite other challenges.

Negative Factors

Negative Cash Flows

Persistent negative cash flows hinder the ability to cover operational needs, posing a risk to financial stability and long-term sustainability.

Ongoing Losses

Ongoing losses and negative profit margins undermine financial performance, limiting reinvestment potential and growth prospects.

Financial Stability Concerns

Negative returns and financial instability can limit strategic options and erode investor confidence, impacting long-term viability.

Clearbridge Health Ltd. Business Overview & Revenue Model

Company Description

Clearbridge Health Limited, an investment holding company, provides healthcare solutions in Singapore, the Philippines, Hong Kong, Malaysia, and internationally. It operates through Strategic Investments, Healthcare Systems, and Medical Clinics/Centres segments. The company provides imaging services, including general x-ray, computerized tomography scan, dental cone beam CT scan, mammography, magnetic resonance imaging, and ultrasound; general health services, such as diabetes, high blood pressure, and high cholesterol screening; and vaccination services, as well as renal care and clinical services. It also offers aesthetics, and dental and orthodontics services, as well as consultancy services for healthcare organization; and wholesales medicinal and pharmaceutical products. Clearbridge Health Limited was incorporated in 2010 and is based in Singapore.

How the Company Makes Money

Clearbridge Health Ltd. generates revenue through multiple streams, primarily by offering diagnostic testing services to healthcare providers and institutions. This includes the sale of genetic tests, which are used for early detection of diseases and personalized treatment plans. The company may also engage in partnerships with pharmaceutical companies and research institutions to provide insights and data that can enhance drug development processes. Additionally, licensing agreements for proprietary technology and tools used in diagnostics can contribute to their earnings. The integration of services into healthcare systems and collaborations with payers for reimbursement models further support their revenue generation.

Clearbridge Health Ltd. Financial Statement Overview

Summary

Clearbridge Health Ltd. is facing significant financial challenges, with ongoing losses and negative cash flows. Despite a stable gross profit margin and moderate debt level, profitability and cash flow generation remain weak, necessitating urgent improvements.

Income Statement

Clearbridge Health Ltd. has experienced a decline in revenue over the past few years, with a slight recovery in the most recent period. However, the company continues to face significant profitability challenges, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains relatively stable, but the overall financial performance is hindered by substantial operating losses.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, indicating a manageable level of leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio suggests a reasonable level of equity financing, but the company's financial stability is compromised by persistent negative returns.

Cash Flow

Clearbridge Health Ltd. has struggled with negative operating and free cash flows, although there is a slight improvement in free cash flow relative to net income. The company faces challenges in generating sufficient cash flow to cover its operational needs, which poses a risk to its financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.42M	9.90M	10.41M	16.41M	11.44M	36.26M
Gross Profit	3.60M	4.78M	5.13M	9.58M	6.36M	13.81M
EBITDA	-1.91M	-2.06M	-32.17M	-7.63M	-7.65M	168.00K
Net Income	-2.14M	-3.61M	-32.20M	-11.14M	-19.97M	615.00K
Balance Sheet
Total Assets	18.08M	21.22M	23.92M	58.18M	82.72M	96.99M
Cash, Cash Equivalents and Short-Term Investments	982.00K	3.17M	4.48M	6.05M	14.55M	14.41M
Total Debt	1.45M	6.24M	7.64M	7.47M	12.74M	20.43M
Total Liabilities	4.16M	10.17M	10.64M	12.51M	25.41M	37.04M
Stockholders Equity	12.21M	9.21M	10.19M	42.32M	52.21M	60.45M
Cash Flow
Free Cash Flow	-1.24M	-2.10M	-4.12M	-2.67M	-3.83M	1.53M
Operating Cash Flow	-1.15M	-1.93M	-3.57M	-1.98M	-2.99M	2.61M
Investing Cash Flow	100.00K	1.18M	3.07M	-1.08M	1.18M	-903.00K
Financing Cash Flow	455.00K	266.00K	-1.88M	-2.56M	2.46M	-1.02M

Clearbridge Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OTX	80 Outperform	S$30.95M	9.27	20.77%	7.30%	-2.08%	129.31%
1B1	67 Neutral	S$53.06M	5.19	47.36%	3.37%	1.58%	115.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1H3	37 Underperform	S$8.59M	-1.21	-137.86%	―	―	―

Clearbridge Health Ltd. Corporate Events

Clearbridge Health Raises S$1.86 Million Through Share Placement

Clearbridge Health Limited has successfully completed a placement of 990 million new ordinary shares, raising approximately S$1.86 million in net proceeds. These funds are primarily allocated to general working capital requirements, with significant portions used for payroll-related expenses, payments to suppliers, professional fees, and rental expenses, which will support the company’s operational needs and financial stability.

Clearbridge Health Launches Adult Immune Cell Banking in Southeast Asia and Hong Kong

Clearbridge Health Limited has launched its adult immune cell banking business, targeting Southeast Asia and Hong Kong. This venture, operated by its subsidiary Cell Entrust Bio Co. Limited, aims to meet the growing demand for autologous immune cell storage, which is crucial for emerging immunotherapy and cellular therapies. The business model is asset-light, leveraging an exclusive partnership with an AABB-accredited biobank, facilitating rapid market entry. This strategic move positions Clearbridge Health to capitalize on the increasing interest in immunotherapy treatments, such as CAR-T therapy, and other cellular therapies, potentially enhancing its industry positioning and stakeholder value.